This page summarizes information about the clinical trials that support investigation of both approved and experimental medicines. This information includes information about the interventions and their sponsoring organizations. Note that these data are derived from ClinicalTrials.gov, with information corrected and disambiguated to convey more accurate detail about these trials. Phase 4 trials are currently excluded on this page by default, as this data will be analyzed separately at a later date.
Trials with Experimental APIs
Top 5 (by most trials)
endostatin (115) interleukin-12 (62) bintrafusp alfa (54) pegylated arginine deiminase (50) lactoferrin (47)Trials with Approved APIs
Top 5 (by most trials)
sargramostim (1573) interferon alpha-2b (912) insulin human (747) aldesleukin (651) Filgrastim (513)Trials with Unapproved APIs
Top 5 (by most trials)
NoneAPIs in Phase 1
Top 5 (by most trials)
sargramostim (457) aldesleukin (302) insulin lispro (177) insulin human (163) Filgrastim (160)APIs in Phase 2
Top 5 (by most trials)
sargramostim (1148) interferon alpha-2b (722) aldesleukin (435) Filgrastim (346) insulin human (344)APIs in Phase 3
Top 5 (by most trials)
interferon alpha-2b (314) sargramostim (242) insulin human (208) insulin glargine (198) epoetin (161)Phase 1 Sponsors
Top 5 (by most trials)
National Cancer Institute (NCI) (444) Novo Nordisk (181) University of Texas at Houston (98) Eli Lilly (92) University of Washington (78)Phase 2 Sponsors
Top 5 (by most trials)
National Cancer Institute (NCI) (757) University of Texas at Houston (191) National Institutes of Health (NIH) (116) Amgen (96) Harvard University (96)Phase 3 Sponsors
Top 5 (by most trials)
Novo Nordisk (202) National Cancer Institute (NCI) (144) Roche (112) Sanofi (110) Eli Lilly (95)